AI-Powered Phenotypic Profiling Revolutionizes Drug Discovery
Today, nine out of ten drugs fail in clinical trials. Furthermore, it takes over a decade and an average cost of $2 billion to develop and approve each medicine.1 An important underlying reason is the gap that exists between cell-based in vitro research and clinical research—often referred to as the “valley of death.” Promising in vitro candidates often fail in the clinic, as in vitro models turn out to be insufficiently predictive and translatable to the clinical setting.
In this article, Angeline Lim, PhD, applications scientist and bioimaging specialist at Molecular Devices, and David Egan, PhD, co-founder and CEO, Core Life Analytics discuss how phenotypic profiling assays, combined with analysis powered by artificial intelligence (AI), is revolutionizing drug discovery.